
Daniel T. McKillop
Partner
201-896-7115 dmckillop@sh-law.comFirm Insights
Author: Daniel T. McKillop
Date: October 2, 2019
Partner
201-896-7115 dmckillop@sh-law.comCuraleaf Holdings (Curaleaf), one of the largest cannabis companies in the country, recently found itself on the receiving end of a stern warning from the U.S. Food and Drug Administration (FDA). The FDA action highlights that businesses in the cannabis industry must be mindful about how they tout their products and that making unsubstantiated claims can lead to costly legal headaches.
CBD products have flooded the market in recent years. While regulators like the FDA have largely taken a hands-off approach to the sale of such products, they are beginning to take a close look at how they are marketed, particularly with respect to health claims.
The FDA warning letter accuses Curaleaf of making unsubstantiated health claims about their cannabidiol (CBD) products and misbranding them as drugs. According to the FDA, Curaleaf’s “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are drugs under Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.” The claims cited in the FDA letter include:
As the FDA states in its warning letter, Curaleaf’s CBD products are not generally recognized as safe and effective for the above-referenced uses and, therefore, are considered “new drugs” under the FD&C Act. This means that they may not be legally introduced into interstate commerce without prior approval from the FDA.
Dietary Supplements
The FDA letter also accuses Curaleaf of misbranding its CBD products as dietary supplements. In support, it cites statements on the company’s website, such as: “Cannabidiol (CBD) is a natural constituent of industrial hemp and is a dietary supplement.” However, as the agency explains, the FDA has concluded based on available evidence that CBD products are excluded from the FD&C Act’s dietary supplement definition.
CBD Pet Products
The FDA’s warning letter also addresses CBD products geared towards pets. As detailed by the FDA, Curaleaf claims that its CBD oil can “Decrease autonomic arousal symptoms like fast/irregular heartbeat, panting, and general distressed feelings” and “Prevent the longer-term health effects of anxiety,” among other claims.
Because the Curaleaf’s products are intended to mitigate, treat, or prevent disease in animals, the FDA considers them drugs. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under the FD&C Act. Because Curaleaf’s products did not satisfy these criteria, the FDA considers them unsafe and adulterated and, thus, marketing them violated the FD&C Act.
Curaleaf has removed the health claims at issue from its website and social media accounts. However, the company may still face liability.
While the FD&C Act does not include a private right of action, an FDA warning letter can lead to related legal action, including lawsuits under the federal Lanham Act and state consumer protection laws for false and misleading advertising. In the case of Curaleaf, it is facing a lawsuit alleging that the company violated Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5, by knowingly making materially false and misleading statements to the investing public that artificially inflated the price of Curaleaf stock.
While the FDA is working on new guidelines for cannabis products, it also appears to be stepping up its scrutiny of health claims about CBD. Before making any claims about the therapeutic value of your CBD products, it is imperative to consult with an experienced cannabis attorney who understands how to navigate the complex and rapidly evolving regulatory landscape.
If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, at 201-806-3364.
This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
If you’re considering closing your business, it’s crucial to understand that simply shutting your doors does not end your legal obligations. Unless you formally dissolve your business, it continues to exist in the eyes of the law—leaving you exposed to ongoing liabilities such as taxes, compliance violations, and potential lawsuits. Dissolving a business can seem […]
Author: Christopher D. Warren
Contrary to what many people think, corporate restructuring isn’t all doom and gloom. Revamping a company’s organizational structure, corporate hierarchy, or operations procedures can help keep your business competitive. This is particularly true during challenging times. Corporate restructuring plays a critical role in modern business strategy. It helps companies adapt quickly to market changes. Following […]
Author: Dan Brecher
Cryptocurrency intimidates most people. The reason is straightforward. People fear what they do not understand. When confusion sets in, the common reaction is either to ignore the subject entirely or to mistrust it. For years, that is exactly how most of the public and even many in law enforcement treated cryptocurrency. However, such apprehension changed […]
Author: Bryce S. Robins
Using chattel paper to obtain a security interest in personal property is a powerful tool. It can ensure lenders have a legal claim on collateral ranging from inventory to intellectual property. To reduce risk and protect your legal rights, businesses and lenders should understand the legal framework. This framework governs the creation, sale, and enforcement […]
Author: Dan Brecher
For years, digital assets operated in a legal gray area, a frontier where innovation outpaced the reach of regulators and law enforcement. In this early “Wild West” phase of finance, crypto startups thrived under minimal oversight. That era, however, is coming to an end. The importance of crypto compliance has become paramount as cryptocurrency has […]
Author: Bryce S. Robins
Earlier this month, the U.S. Supreme Court issued a decision in Ames v. Ohio Department of Youth Services vitiating the so-called “background circumstances” test required by half of federal circuit courts.1 The background circumstances test required majority group plaintiffs pleading discrimination under Title VII of the Civil Rights Act to meet a heightened pleading standard […]
Author: Matthew F. Mimnaugh
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!